Brazil could approve a new anti-Covid-19 drug by Tuesday, when federal regulator Anvisa will hold a board meeting to discuss a request by Swiss health conglomerate Roche and Regeneron, a U.S.-based pharmaceutical company.
According to specialized website Pharmaceutical Technology, Roche reports that phase-three trials of Regen-Cov — its antibody cocktail of casirivimab and imdevimab — met its primary objective of reducing the risk of hospitalization or death among high-risk and non-hospitalized Covid-19 patients by 70 percent.
The U.S. Food and Drug Administration gave Regen-Cov emergency approval for use by mild to moderate Covid-19 patients. “This data paves the way for [antibody therapy] Regen-Cov to be used before patients become symptomatic, with a more convenient subcutaneous administration,” said Katharine Bar, co-principal investigator and a professor at the University of Pennsylvania hospital, in a Regeneron press release.
Search
